Navigation Links
/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
Date:9/2/2008

-RAS mutations.

"Previous preclinical data indicates that reovirus tends to localize in the lungs, and we have seen clinical responses in metastatic lung lesions with REOLYSIN(R) as a monotherapy or in combination with paclitaxel and carboplatin," said Dr. Brad Thompson, President and CEO of Oncolytics. "A significant clinical opportunity for REOLYSIN(R) is in the treatment of patients with metastatic cancers including NSCLC who have a mutated K-RAS gene and are unlikely to respond to treatment with EGF receptor inhibitors."

About Lung Cancer

Lung cancer is the second most common cancer in men and women and is the leading cause of cancer death. More people die of lung cancer than of colon, breast and prostate cancers combined. During 2008, there will be about 215,020 new cases of lung cancer in the U.S., of which 85% to 90% will be NSCLC. Only about 15% of people diagnosed with lung cancer are still alive after five years. There is no single, first-line therapy approved for NSCLC in the U.S., but first-line combination treatments include avastin/paclitaxel/carboplatin, vinorelbin/cisplatin, gemcitabine/cisplatin, paclitaxel/cisplatin and docetaxel/cisplatin. Other therapies approved for second and third-line treatments are used as well. For more information about lung cancer, please go to http://www.cancer.org.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase 1/2 and Phase 2 human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking state
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
4. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
5. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
7. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
8. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
9. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... OR (PRWEB) August 27, 2014 According ... “Consolidation continues to reshape the look and feel of ... Consumer demand for higher-quality ingredients will push for more ... American market have experienced strong market growth in the ... attributes in their food and cosmetics to fit a ...
(Date:8/26/2014)... the thinnest-possible semiconductor, a new class of nanoscale ... , The University of Washington researchers have demonstrated ... be connected in an atomically seamless fashion known ... basis for next-generation flexible and transparent computing, better ... "Heterojunctions are fundamental elements of electronic and photonic ...
(Date:8/26/2014)... MA (PRWEB) August 26, 2014 The ... Faces of ALS (YFALS) community issued the following statement ... movement bringing awareness and driving new funding specifically for ... bucket of water and some ice would raise all ... together with our families, and on behalf of the ...
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed ... strains in Pubmed, has revealed extensive conservation and sharing ... and sharing of specific Replikin gene structures has permitted ... it did for the H5N1 influenza vaccine and the ... found to be effective (1,2). This ...
Breaking Biology Technology:Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4
... April 15 ,BioHorizons, Inc. ("BioHorizons") announced today the ... ("ILS"), first announced on January,30, 2008. Implant Logic ... Boggan, CEO of BioHorizons, commented, "We are excited,to ... Implant Placement,planning software and CAD/CAM surgical guides. This ...
... Pain-Management Market ... ... Inc. (NYSE: AOB ), a leading marketer, distributor and,manufacturer ... Company, Inc. (OTC Bulletin Board: CAXG) ("China,Aoxing"), a China-based pharmaceutical ...
... Designs Comforting Environment for Patients and Families, ... Medical,Center celebrates the opening of two new health ... treatment options for,life-threatening illnesses and to offer health ... seamless delivery of screening and,diagnostic procedures, all in ...
Cached Biology Technology:BioHorizons Announces the Purchase of Implant Logic Systems 2American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 2American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 3American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 4Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 2Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 3
(Date:8/27/2014)... have shown that excessive iron is closely ... Previous studies from Chunyan Guo and co-workers ... shown that baicalin prevented iron accumulation after ... 1 expression, and increased ferroportin 1 expression ... disease rats. However, the relationship between iron ...
(Date:8/27/2014)... As of seven hours ago the Happy Camp Complex ... Northern California, the July complex had consumed 35,530 as ... seventeen fires on the Happy Camp Ranger District of ... the area on August 11, 2014. All but three ... following is a list of contained fires and their ...
(Date:8/27/2014)... Researchers from North Carolina State University have found that century-old ... affect a common insect pest that can weaken and kill ... studies found that scale insect populations increase on oak and ... that these pests may also increase with global warming," says ... lead author of a paper on the work. , "More ...
Breaking Biology News(10 mins):Happy Camp and July Fire Complexes in California 2Museum specimens, modern cities show how an insect pest will respond to climate change 2
... cells are encased within a protective lipid membrane. The ... that transport nutrients, ions, and water into and out ... recognize each other in the body, and make the ... mapped out nearly all of the membrane proteins in ...
... must be standardized among laboratories and across platforms around ... exploration, an Oregon Health & Science University researcher says. ... gene chips, risk having their research results called into ... the OHSU School of Medicine. , Spencer, director of ...
... development requires billions of neurons to migrate to the appropriate ... connect to other nerve cells in an intricate network. Growth ... for steering axons in the right direction, guided by a ... way. Some signals lure the axons to extend and grow ...
Cached Biology News:Study: 'homemade' gene expression technology unreliable 2Study: 'homemade' gene expression technology unreliable 3Cerebral navigation: How do nerve fibers know what direction to grow in? 2
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
... Goat polyclonal to Cholesterol Oxidase ... / Specificity Cross-reacts with bacteria. Not ... Information Cholesterol oxidases exist as both ... are implicated in bacterial pathogenesis. In addition, ...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
MDMA Mouse Monoclonal Antibody (Clone 3G8)...
Biology Products: